Madrigal Pharmaceuticals (MDGL)
(Real Time Quote from BATS)
$219.00 USD
+7.68 (3.63%)
Updated May 14, 2024 10:12 AM ET
3-Hold of 5 3
F Value F Growth F Momentum F VGM
Income Statements
Fiscal Year end for Madrigal Pharmaceuticals, Inc falls in the month of December .
All items in Millions except EPS data.
12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 | |
---|---|---|---|---|---|
Sales | 0 | 0 | 0 | 0 | 0 |
Cost Of Goods | 0 | 0 | 0 | 0 | 0 |
Gross Profit | 0 | 0 | 0 | 0 | 0 |
Selling & Adminstrative & Depr. & Amort Expenses | 381 | 294 | 242 | 207 | 95 |
Income After Depreciation & Amortization | -381 | -294 | -242 | -207 | -95 |
Non-Operating Income | 20 | 2 | 1 | 4 | 11 |
Interest Expense | 13 | 4 | 0 | 0 | 0 |
Pretax Income | -374 | -295 | -242 | -202 | -84 |
Income Taxes | 0 | 0 | 0 | 0 | 0 |
Minority Interest | 0 | 0 | 0 | 0 | 0 |
Investment Gains/Losses | 0 | 0 | 0 | 0 | 0 |
Other Income/Charges | 0 | 0 | 0 | 0 | 0 |
Income From Cont. Operations | -374 | -295 | -242 | -202 | -84 |
Extras & Discontinued Operations | 0 | 0 | 0 | 0 | 0 |
Net Income (GAAP) | -374 | -295 | -242 | -202 | -84 |
Depreciation Footnote | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Income Before Depreciation & Amortization | -378 | -292 | -242 | -206 | -95 |
Depreciation & Amortization (Cash Flow) | 3 | 1 | 0 | 0 | 0 |
Income After Depreciation & Amortization | -381 | -294 | -242 | -207 | -95 |
Earnings Per Share Data | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Average Shares | 18.69 | 17.14 | 16.54 | 15.45 | 15.40 |
Diluted EPS Before Non-Recurring Items | -19.99 | -17.23 | -14.63 | -13.09 | -5.45 |
Diluted Net EPS (GAAP) | -19.99 | -17.23 | -14.63 | -13.09 | -5.45 |
Fiscal Year end for Madrigal Pharmaceuticals, Inc falls in the month of December .
All items in Millions except EPS data.
3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 | 3/31/23 | |
---|---|---|---|---|---|
Sales | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Cost Of Goods | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Gross Profit | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
SG&A, R&D, and Dept/Amort Expenses | 152.04 | 117.18 | 98.53 | 86.46 | 78.33 |
Income After SG&A, R&D, and Dept/Amort Expenses | -152.04 | -117.18 | -98.53 | -86.46 | -78.33 |
Non-Operating Income | 8.33 | 8.95 | 3.30 | 3.55 | 3.78 |
Interest Expense | 3.84 | 3.97 | 3.50 | 2.90 | 2.34 |
Pretax Income | -147.54 | -112.19 | -98.74 | -85.80 | -76.90 |
Income Taxes | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Minority Interest | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Investment Gains/Losses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Other Income/Charges | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Income From Cont. Operations | -147.54 | -112.19 | -98.74 | -85.80 | -76.90 |
Extras & Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Net Income (GAAP) | -147.54 | -112.19 | -98.74 | -85.80 | -76.90 |
Earnings Per Share Data | 3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 | 3/31/23 |
---|---|---|---|---|---|
Average Shares | 20.00 | 19.76 | 18.48 | 18.31 | 18.19 |
Diluted EPS Before Non-Recurring Items | -7.38 | -5.68 | -5.34 | -4.69 | -4.23 |
Diluted Net EPS (GAAP) | -7.38 | -5.73 | -5.34 | -4.69 | -4.23 |